Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by StockNews.com

Analysts at StockNews.com assumed coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research report issued on Friday. The firm set a “sell” rating on the stock.

Syros Pharmaceuticals Price Performance

Shares of NASDAQ SYRS opened at $0.03 on Friday. The company has a market cap of $845,208.00, a P/E ratio of -0.01 and a beta of 1.31. The firm has a 50-day simple moving average of $0.04 and a two-hundred day simple moving average of $0.33. Syros Pharmaceuticals has a 1 year low of $0.02 and a 1 year high of $6.93.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Syros Pharmaceuticals stock. Two Sigma Securities LLC acquired a new stake in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 107,742 shares of the company’s stock, valued at approximately $25,000. Two Sigma Securities LLC owned about 0.40% of Syros Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). 91.47% of the stock is currently owned by institutional investors and hedge funds.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.